Gabapentin is NOT Recommended for Numbness and Tingling from Spinal Compression Radiculopathy
Based on the highest quality guideline evidence, gabapentin should not be used for spinal compression radiculopathy, as it has consistently failed to demonstrate efficacy for this specific condition and is associated with significant adverse effects without meaningful benefit.
Evidence Against Gabapentin for Radiculopathy
The 2017 American College of Physicians systematic review 1 found that three poor-quality trials of gabapentin (doses 1200-3600 mg/day) for chronic radicular back pain showed inconsistent findings with pain reduction effects ranging from only 0.3 to 1.9 points on a 0-10 scale—clinically insignificant improvements. This guideline represents the most recent and comprehensive synthesis of evidence.
The 2010 Mayo Clinic neuropathic pain guidelines 2 explicitly identify lumbosacral radiculopathy as a neuropathic pain condition that is relatively refractory to existing first- and second-line medications, including gabapentin. The guidelines note that "recent trials of nortriptyline and morphine and their combination and pregabalin and an equivocal trial of topiramate suggest that lumbosacral radiculopathy might be a third peripheral NP condition that is relatively refractory to existing first- and second-line medications."
Supporting Research Evidence
The most rigorous head-to-head trial 3 comparing epidural steroid injection versus gabapentin in 145 patients with lumbosacral radicular pain found no significant differences in leg pain at 1 month (mean pain scores 3.3 vs 3.7, p=0.25) or 3 months (3.4 vs 3.7, p=0.43). While some secondary outcomes favored epidural injection at 1 month, the differences were modest and transient.
A 2025 double-blind randomized placebo-controlled trial 4 in 90 LSS patients found that gabapentin (1800 mg/day) showed no superiority over placebo in reducing neurogenic claudication pain, functional outcomes, or quality of life at any time point over 4 months. Critically, gabapentin was associated with significantly higher rates of dizziness and sedation (p<0.001).
Safety Concerns
A 2026 retrospective cohort study 5 of 23,379 matched patients with cervical radiculopathy found that gabapentin prescription was associated with significantly increased risks compared to NSAIDs:
- Opioid-related disorder (RR: 2.87)
- Opioid-related adverse events (RR: 2.32)
- Acute respiratory failure (RR: 1.80)
- Inpatient visits (RR: 1.38)
- Oral opioid prescription (RR: 1.34)
No outcome favored gabapentin over NSAIDs.
Why Radiculopathy Differs from Other Neuropathic Pain
The FDA label 6 confirms gabapentin's approval only for postherpetic neuralgia and epilepsy—not radiculopathy. The mechanism of radicular pain from mechanical compression differs fundamentally from the peripheral nerve injury patterns seen in postherpetic neuralgia or diabetic neuropathy, where gabapentin has demonstrated efficacy.
Clinical Bottom Line
Do not prescribe gabapentin for numbness and tingling from spinal compression radiculopathy. The evidence shows:
- No consistent benefit over placebo
- Increased risk of adverse effects including sedation, dizziness, and opioid co-prescription
- Increased healthcare utilization without improved outcomes
- This condition is specifically identified as refractory to gabapentinoids in guidelines
Alternative approach: Focus on physical therapy, time-limited NSAIDs for inflammation, and consideration of epidural steroid injection if conservative measures fail, while monitoring for progressive neurological deficits that would warrant surgical evaluation.